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REKABENTUK DAN PENILAIAN TABLET MATRIKS BERLAPIS 
PELEPASAN TERKAWAL PARASETAMOL DAN VERAPAMIL HCl 
 
ABSTRAK 
 
Tablet matriks berlapis pelepasan terkawal parasetamol dan verapamil HCl 
dibangunkan menggunakan polimer hidrofilik dan hidrofobik, dan disediakan dengan 
kaedah pengranulan basah. Tablet matriks parasetamol teras, dua dan tiga lapis 
diformulasikan menggunakan polimer hidrofilik (Metolose 60SH) dan hidrofobik 
(Ethocel 10cP). Tablet matriks teras mengandungi Metolose 60SH pada kepekatan 
yang berbeza (5, 10, 15 dan 20%) manakala lapisan terdiri daripada  Metolose 60SH 
(10 dan 20%) atau Ethocel 10cP (5 dan 10%) atau gabungan kedua-dua polimer. 
Kepekatan polimer di dalam teras dan lapisan berkadar songsang dengan kadar 
pelepasan drug daripada tablet matriks. Jenis polimer juga mempengaruhi pelepasan 
drug dari pada tablet matriks berlapis. Lapisan hidrofilik memanjangkan pelepasan 
drug manakala lapisan hidrofobik tidak ada kesan. Walau bagaimanapun, tablet 
matriks tiga lapis yang mengandungi campuran Methocel 60SH (20%) dan Ethocel 
10cP (10%) dalam lapisan mempunyai jangkamasa pelepasan drug yang paling 
tertahan dengan nilai T50% 10.97 jam dan MDT 10.50 jam. Pelepasan drug daripada 
sediaan mengikut kinetik tertib sifar. Oleh itu, tablet matriks parasetamol tiga lapis 
yang  mengandungi polimer hidrofilik dan hidrofobik mempunyai pelepasan drug 
yang paling tertahan. Tablet matriks verapamil HCl teras, dua dan tiga lapis 
disediakan menggunakan beberapa kepekatan polimer hidrofilik Methocel K15M 
dan K100M (5, 10, 15 dan 20%), dan polimer hidrofobik Ethocel 10cP (5, 10, 15, 20 
dan 30%). Sebagai tambahan, beberapa kepekatan asid suksinik (5, 10, 15 dan 20%) 
dimasukkan ke dalam teras. Formulasi dengan asid suksinik 15% di dalam teras 
  xxxi
didapati yang paling bagus untuk menghasilkan pelepasan drug daripada tablet 
matriks yang tidak bergantung kepada pH. Kepekatan polimer di dalam teras 
berkadar songsang dengan kadar pelepasan drug daripada tablet matriks. Pada 
amnya, pelepasan drug daripada teras yang mengandungi polimer hidrofilik adalah 
lebih perlahan daripada teras yang mengandungi polimer hidrofobik. Matriks tablet 
dua dan tiga lapis disediakan dengan pelbagai kepekatan polimer di dalam teras dan 
lapisan tetapi jumlah amaun polimer tetap malar. Formulasi mengandungi polimer 
hidrofilik di dalam teras dan lapisan menghasilkan pelepasan drug lebih tertahan 
daripada formulasi mengandungi polimer hidrofobik di dalam teras dan lapisan. 
Tablet matriks tiga lapis yang mengandungi Methocel K100M di dalam teras 
(11.25%) dan lapisan (3.75%) mempunyai jangkamasa pelepasan drug yang paling 
tertahan dengan T50% 10.20 jam, MDT 10.49 jam dan mengikuti kinetik tertib sifar. 
Sebelum melakukan kajian in vivo, kaedah HPLC mudah dan sensitif dengan 
pengesanan pendarfluor disahkan untuk penetuan severapamil dan norverapamil 
secara serentak pada plasma arnab, menggunakan propranolol sebagai piawai 
internal. Sebagai tambahan, kajian in vivo rekabentuk  saling melintang dua arah 
dilakukan ke atas enam ekor arnab untuk membandingkan biokeperolehan tablet 
matriks hidrofilik tiga lapis dengan Isoptin® SR sebagai produk rujukan. Tiada 
perbezaan pada nilai Tmax, Cmax dan AUC antara tablet matriks tiga lapis verapamil 
HCl dan Isoptin® SR. Oleh itu, tablet matriks verapamil HCl tiga lapis mempunyai 
kadar dan takat penyerapan yang sama seperti Isoptin® SR. 
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DESIGN AND EVALUATION OF CONTROLLED RELEASE LAYERED 
MATRIX TABLETS OF PARACETAMOL AND VERAPAMIL HCl  
 
 
ABSTRACT  
 
 
Controlled release layered matrix tablets of paracetamol and verapamil HCl were 
developed using hydrophilic and hydrophobic polymers by the wet granulation 
method. Paracetamol core, two and three layered matrix tablets were formulated 
using hydrophilic (Metolose 60SH) and hydrophobic (Ethocel 10cP) polymers. The 
core matrix tablets contained different concentrations (5, 10, 15 and 20%) of 
Metolose 60SH while the layers consisted of either Metolose 60SH (10 and 20%) 
and/or Ethocel 10cP (5 and 10%) and combinations of both polymers. Polymer 
concentrations in the core and layers were found to be inversely proportional with the 
drug release rate from the matrix tablets. Polymer types also influenced the drug 
release from the layered matrix tablets. Hydrophilic layers prolonged the drug release 
whilst hydrophobic layers had no effect. However, a three layered matrix tablet 
containing a mixture of Metolose 60SH (20%) and Ethocel 10cP (10%) in the layers 
had the most sustained duration of drug release with T50% values of 10.97 hours and 
MDT of  10.50 hours. The drug release from the preparation followed zero order 
kinetics. Therefore, the paracetamol three layered matrix tablets containing mixture 
of hydrophilic and hydrophobic polymers had the most sustained drug release. 
Verapamil HCl core, two and three layered matrix tablets were prepared using 
several concentrations of hydrophilic polymers Methocel K15M and K100M (5, 10, 
15 and 20%), and hydrophobic polymers Ethocel 10cP and 100cP (5, 10, 15, 20 and 
30%). Different concentrations of succinic acid (5, 10, 15 and 20%) were 
additionally incorporated into the core. Formulation with succinic acid 15% in the 
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core was found to be the best in producing pH independent drug releases from the 
hydrophilic and hydrophobic matrix tablets. Polymer concentrations in the core were 
inversely proportional to the drug release rate from the matrix tablets. In general, 
drug release from core containing hydrophilic polymers was slower than core 
containing hydrophobic polymers. The two and three layered matrix tablets were 
prepared by varying the concentrations of polymers in the core and layers whilst 
keeping the total amount of the polymer in the tablet constant. Formulations 
containing hydrophilic polymers in the core and layers produced more sustained drug 
release than formulations containing hydrophobic polymers in the core and layers. 
Three layered matrix tablets containing Methocel K100M in the core (11.25%) and 
layers (3.75%) had the most sustained drug release profiles with T50% of 10.20 hours, 
MDT of 10.49 hours and followed zero order kinetics. Prior to conducting the in vivo 
study, a simple and sensitive HPLC method with fluorescence detection was 
validated for the simultaneous determination of verapamil and norverapamil in rabbit 
plasma, using propranolol as an internal standard. In vivo study with a two-way 
crossover design was performed on six rabbits to compare the pharmacokinetic 
parameters of the hydrophilic three layered matrix tablets and Isoptin® SR as the 
reference product. There were no differences in Tmax, Cmax and AUC values between 
the verapamil HCl three layered matrix tablets and Isoptin® SR. Therefore, the 
verapamil HCl three layered matrix tablets containing the hydrophilic polymer had a 
similar rate and extent of absorption as Isoptin® SR. 
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Chapter 1 
Introduction 
1.1 Controlled release drug delivery system 
Oral route still remains the most popular for drug administration by virtue of its 
convenience to the patient. A sizable portion of orally administered dosage forms, so 
called conventional, are designed to achieve maximal drug bioavailability by 
maximizing the rate and extent of absorption. Whilst such dosage forms have been 
useful, frequent daily administration is necessary, particularly when the drug has a 
short biological half life. This may result in wide fluctuation in peak and trough 
steady-state drug levels, which is undesirable for drugs with marginal therapeutic 
indices. Moreover, patient compliance is likely to be poor when patients need to take 
their medication three to four times daily on chronic basis. Fortunately, these 
shortcomings have been circumvented with the introduction of controlled release 
dosage forms. These dosage forms are capable of controlling the rate of drug 
delivery, leading to more sustained drug levels and hence therapeutic action as 
outlined in Fig.1.1. 
 
During past few decades, significant advance have been made in the area of 
controlled release as evidenced by an increasing number of patents, publication, as 
well as commercial controlled release products for the delivery of variety of 
pharmaceutical compounds. With a controlled release formulation a predictable and 
reproducible release rate can be achieved, at the target site for desired duration. This 
results in optimum biological response, prolonged efficacy, decreased toxicity as 
well as reduction in required dose levels as compared to the conventional mode of 
delivery (Wilding et al., 1991). 
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Fig.1.1: Schematic drawing of plasma concentration-versus-time profiles following 
administration of three immediate-release dosage forms versus one single 
controlled-release dosage form (Brahmankar et al., 2000). 
 
 
The first truly effective oral drug delivery system, the “Spansule” was introduced in 
the 1950s. This prolonged release system was marketed by SmithKline & French 
Laboratories and consisted of small coated beads placed in a capsule (US Patent No. 
2738303). 
 
Matrix tablets which were prepared by compressing granules to form matrices 
appeared in 1959 (British Patent No. 808014). The inherent drawback of the matrix 
system is its first order release behavior. For most controlled dosage forms zero order 
release may be the “holy grail”. To overcome the inherent preponderant first order 
release behavior with continuously diminishing release rate from matrix systems, 
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geometry factors have been utilized to compensate for the increasing diffusional 
distance and decreasing area at the penetrating diffusion front generally encountered 
in matrix system. Geomatrix is a delivery device, in the form of a multi-layer tablet, 
proposed for constant drug release. It consists of matrix core, containing the active 
ingredient, and one or two impermeable or semi-permeable polymeric barriers 
compressed on one or both faces of the core. These barrier layers provide a 
modulation of the drug dissolution profile; they reduce the release rate from the 
tablets and are shown to be effective in obtaining zero order release (Colombo et al., 
1989; Colombo et al., 1990; Colombo et al., 1992; Conte et al., 1992; Conte et al., 
1993; Conte et al., 1994).   
 
A geomatrix system has few advantages. A conventional high-speed tableting 
machine can be used to produce geomatrix tablets with a high degree of product 
consistency and uniformity. This system can be applied to a wide range of drug 
molecules, including some with poor water solubility and can target the site of 
release. The major advantage of this system being its ability to control the rate of 
drug diffusion throughout the release process, ensuring 100% release of the active 
drug. Moreover, the geomatrix technologies can improve drug efficacy and enhance 
patient compliance.  
 
1.2 Advantages and disadvantages of controlled release delivery system 
Controlled release technology may provide increased clinical value as well as 
extended product life. The advantages of an ideal controlled release dosage form 
over an immediate release product include improved patient compliance due to a 
reduced dosing frequency, a decreased incidence and/or intensity of the side effects, 
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greater selectivity of pharmacological activity and more prolonged therapeutic effect 
as well as an increase of cost effectiveness. 
 
However, the controlled release dosage forms also possess some disadvantages. 
Potential disadvantages of controlled release dosage form include the possibility of 
dose dumping, less facile dose adjustment, increased potential for hepatic first-pass 
metabolism, possible delay in onset of action and possibly poor system availability. 
 
1.3 Controlled release mechanism of drug 
Mechanisms of drug release from oral controlled delivery systems can be broadly 
divided into following categories:  
1.3.1 Dissolution controlled release 
         1.3.1 (a) Matrix dissolution control 
         1.3.1 (b) Reservoir dissolution control 
1.3.2 Diffusion controlled release  
         1.3.2 (a) Matrix diffusion control 
         1.3.2 (b) Reservoir diffusion control  
1.3.3 Osmotic controlled release 
1.3.4 Ion exchange resins 
1.3.5 Gastroretentive systems 
1.3.6 Regulated systems  
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1.3.1 Dissolution controlled release 
Dissolution controlled release can be obtained by slowing down the dissolution rate 
of  a drug in the GI medium, incorporating the drug in an insoluble polymer, and 
coating drug particles or granules with polymeric materials of varying thickness. 
 
1.3.1 (a) Matrix dissolution control 
In these systems, the drug is homogeneously dispersed throughout a rate controlling 
membrane. The drugs which are highly water soluble can also be formulated as 
controlled release products by controlling their dissolution rate using slowly soluble 
polymers. Waxes such as beeswax, carnauba wax and hydrogenated castor oil have 
been used. The wax embedded drug is generally prepared by dispersing the drug in 
molten wax, congealing and granulating them (Robinson, 1990; Lloyd, 1999; 
Varshosaz, 2006). 
 
1.3.1 (b) Reservoir dissolution control 
 In reservoir dissolution controlled system the drug particles are coated or 
encapsulated by one of the several microencapsulation techniques with slowly 
dissolving materials like cellulose derivates, polyethylene glycols, 
polymethacrylates, waxes etc. The resulting reservoirs (coated beads, multi-
particulate system, pellets) may be filled as such in hard gelatin capsules (Spansules) 
or compressed into tablets (Biju et al., 2004). The common multi-particulate systems 
are microparticles (microspheres or microcapsules), nanoparticles (nanospheres or 
nanocapsules) and liposomes. 
 
 
 6
1.3.2 Diffusion controlled release 
Diffusion of a drug molecule through a polymeric membrane forms the basis of this 
controlled drug delivery system. Similar to the dissolution controlled devices, these 
are manufactured either by encapsulating the drug particle in a polymeric membrane 
or by dispersing the drug in a polymeric matrix. 
 
1.3.2 (a)  Matrix diffusion control 
Matrix devices are very common because of ease of fabrication. Diffusion controlled 
involves dispersion of drug in either water-insoluble or a hydrophilic polymer (Khan 
and Reddy, 1997; Viega et al., 1997; Viega et al., 1998). Drug release from insoluble 
matrices involves penetration of fluid, followed by dissolution of the drug particles 
and diffusion through fluid filled pores. In case of soluble matrix containing 
swellable hydrophilic substances the drug becomes available as the matrix swells or 
dissolves and swollen matrix then undergoes surface erosion with little or no bulk 
erosion. The surface area of the matrix decreased with the time, with a concomitant 
decrease in the drug release. The diffusion depends on the solubility of the drug in 
the polymer. The drug may either present below its solubility limit and dissolved in 
the polymer or present well above its solubility limit and dispersed in the polymer 
(Lloyd et al., 1999; Robinson et al., 1990; Marible et al., 2004; Varshosaz, 2006). 
Bupropion hydrochloride (Zyban, GlaxoWellcome) is formulated using carnauba 
wax and hydroxypropylmethyl cellulose (Biju et al., 2004). 
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1.3.2 (b) Reservoir diffusion control 
 A core of drug is coated with the water insoluble polymer. The polymer can be 
applied by coating or microencapsulating technique. The drug release mechanism 
across the membrane involves diffusion of dissolution media through the membrane 
to the inside of the core, then dissolution of the drug and diffusion of the drug into 
the surrounding fluid. Materials used in such devices are hydroxypropyl cellulose, 
ethyl cellulose and polyvinyl acetate. The reservoir diffusion products are Plateau 
CAPS capsules (nicotinic acid), Nio-bid (nitroglycerine) and Brankadyl SR cap 
(theophylline) (Robinson et al., 1990; Sajeev et al., 2002; Mukerjee et al., 2005). 
 
1.3.3 Osmotic controlled release 
Oral osmotic pump, popularly known as ORAS® based on principle of osmotic 
pressure to release the drug at constant rate. The rate of drug release from the 
products is determined by the constant in flow of the water across semi-permeable 
membrane into reservoir, which contains osmotic agents. The drug is either mixed 
with the agent or is located in the reservoir. The dosage form contains a small hole 
from which the dissolved drug moves out at a rate determined by the rate of entrance 
of water due to osmotic pressure. The rate of release is constant and can be 
controlled within tight limits yielding relatively constant blood concentrations. The 
advantage of this type of product is that the release is unaltered by the environment 
of the GIT and it relies simply on the passage of the water into the dosage form. 
Altering the osmotic agent and the size of the hole can modify the rate of release. An 
example of this type of product is Adalat Oros (Nifedipine) (Prabakaran et al., 2003). 
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1.3.4 Ion exchange resins 
Drugs can be bound to ion exchange resins and when ingested, the ionic environment 
within the GIT determines the release of the drug. The drug is released slowly by 
diffusion mechanism from the resins particle structure. Examples of these types of 
products are Duromine containing the basic drug phentermine complex onto an 
anionic resin and MS Contin (morphine sulphate) suspension which uses a 
polystyrene sulphonate resin (Lloyd et al., 1999; Anand et al., 2001). 
 
1.3.5 Gastroretentive systems  
Variability in GI transit time is a concern for oral controlled drug delivery system 
(Deshpande et al., 1996). Drugs with a narrow absorption window in the GI tract are 
particularly susceptible to variation in both bioavailability and times to achieve peak 
plasma levels. Gastroretentive controlled release formulations could offer a potential 
solution to the problem by offering a prolonged gastric residence time (Hwang et al., 
1998). Gastroretentive delivery systems (GRDS) are beneficial for such drugs by 
improving their bioavailability, therapeutic efficacy and by possible reduction of 
dose. Apart from these advantages, these systems offer various pharmacokinetic 
advantages like maintenance of constant therapeutic levels over a prolonged period. 
This would lead to reduction in fluctuation in therapeutic levels and therefore 
minimizing the risk of resistance especially in case of antibiotics. Gastrointestinal 
retention depends on many factors such as density of the dosage form, size of the 
dosage form, fasting and fed condition, nature of the meal taken, sleep, posture etc.  
It also depends strongly on a complicated and unpredictable gastric emptying with 
migrating myoelectric complex motility of the stomach (Talukder and Fassihi, 2004). 
Various delivery systems like floating, swellable, mucoadhesive, high-density 
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formulations, etc., have been developed to achieve gastroretention (Baumgartner et 
al., 2000; Li et al., 2003). 
 
1.3.6 Regulated systems  
These devices are capable of releasing therapeutic agents by well defined kinetics 
and have significant improvement over conventional controlled release systems. In 
these devices drug output is adjusted in response to a physiological need. Regulated 
systems can be classified into two, one is externally regulated system and the other is 
self-regulatory system. Externally regulated devices can alter their drug output only 
in response to an intervention externally. For example, control of diabetes is 
achieved by delivering insulin in response to blood glucose levels. While, self 
regulated devices can act without external intervention. The response to changes in 
temperature or pH within the system leads to drug release. An example of this type 
of system is insulin release from pH sensitive polymers. This approach utilizes pH 
changes resulting from the conversion of glucose to gluconic acid by glucose 
oxidase. Increase in glucoronic level would reduce the pH, which lead to erosion of 
polymer and insulin release.  
 
1.4 In vitro evaluation of controlled release formulations 
1.4.1 Dissolution studies  
 
Dissolution and drug release tests are in vitro tests that measure the rate and extent of 
dissolution or release of drug substances from products, usually in an aqueous 
medium under the specified conditions. Dissolution apparatus is shown in Fig. 1.2. 
Dissolution test is an important quality control for the drug product and is often 
linked to the product performance in vivo. In vitro dissolution studies are most often 
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used for monitoring drug product stability and manufacturing process control. 
Official book such as United States Pharmacopeia (USP) sets standard for dissolution 
of most drug products.  
 
 
 
Fig.1.2: Dissolution apparatus (Distek 2000) (Leon et al., 2004). 
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1.4.2 Dissolution conditions 
The development of an appropriate dissolution test requires the investigator to try 
different agitation rates, different media (including volume and medium) and 
different kind of dissolution apparatus. The rate of agitation and nature of the stirrer 
effect the hydrodynamic of the system (Fig. 1.3), thereby affecting the dissolution 
rate. Stirrings rates must be controlled and the specification differs between the drug 
products. The temperature of the dissolution medium must be controlled and 
variation in temperature must be avoided. Most of the dissolution tests were 
performed at 370C and the current USP 28 lists officially recognized dissolution 
apparatus. Once suitable dissolution test is obtained, acceptable dissolution criteria 
are developed for the drug product and its formulation. The nature of the dissolution 
medium will also affect the dissolution test. The solubility of the drug must be 
considered as well as the total amount of the drug in the dosage form. The 
dissolution medium should not be saturated by the drug (i.e, sink conditions are 
maintained). Usually, a volume of the medium larger than the amount of the solvent 
needed to completely dissolve the drug is used in the dissolution test.  
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Fig. 1.3: Dissolution testing apparatus (USP 28), basket (I) and paddle (II) (Melia et 
al., 1989). 
 
 
1.4.3 Compendial methods of dissolution 
The USP 28 provides several official methods for carrying out dissolution tests of 
tablets, capsules and other special products such as transdermal preparations. Tablets 
are grouped into uncoated and enteric coated tablets. The selection of a particular 
method for a drug is usually specified in the monograph for a particular drug product. 
Table 1.1 lists various types of dissolution apparatus and the type of drug products 
that is often used in apparatus. 
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1.4.4 Dissolution studies for modified release dosage forms 
The following factors need to be considered in selecting of dissolution conditions for 
evaluation of controlled release dosage forms. 
1.  Reproducibility of the method 
2. Proper choice of medium 
3. Maintenance of the sink conditions 
4. Control solution hydrodynamic 
5. Dissolution rate as a function of pH, ranging from pH 1 to pH 8 and including 
several intermediate values  
6. Selection of most discriminating variable (medium, pH and rotation speed etc) as 
the basis for dissolution test and specification 
 
1.4.5 Dissolution method selection              
If a compendial dissolution method and specifications are not available for a drug 
molecule then the following criteria needs to be considered in selection of an 
appropriate dissolution media and to set the specification limits (Skelly and Barr, 
1987). 
 
1 The narrow limit of quantity to be dissolved at the hour time point need to be 
included in the dissolution specification so as to consider no dose dumping is 
taking place from the controlled release formulation. 
2 Appropriate number of time points need to placed in a specification so as to 
describe the controlled release characteristics of the dosage form for whole period 
of study.  
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3 At the last time point of collection a minimum of 75 to 80% of the drug should be 
released from the dosage form. 
4 The pH dependence/independence of the dosage form should be checked by 
carrying out the dissolution in water and appropriate buffers. 
 
1.5 Paracetamol  
 
It is widely used non-prescription, non-narcotic analgesic antipyretic (Prescott and 
Wright, 1973; Walson et al., 1989). Chemical name of paracetamol is N-Acetyl-p-
aminophenol. Molecular formula C8H9NO2 and chemical structure of paracetamol is 
shown in Fig.1.4.  
H
N
O
CH3
OH
 
Fig.1.4: Structural formula of paracetamol 
 
Molecular weight of paracetamol is 151.2 with melting point in the range of 1690C 
and 170.50C. Paracetamol is a white crystalline powder, sparingly soluble in cold 
water but greater solubility in hot water. It is soluble in methanol, ethanol, 
dimethylformamide, ethylene dichloride, acetone and ethyl acetate. But it is slightly 
soluble in ether and insoluble in petroleum ether, pentane and benzene. According to 
Biopharmaceutical Classification System (BCS), it is a class I drug (high soluble and 
high permeable drug) (Chi-Yuan and Leslie, 2005) and it has the log P value of 0.44 
(Burya et al., 2000). 
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1.5.1 Clinical pharmacology 
Paracetamol also known as acetaminophen is a non-steroidal anti-inflammatory drug 
with potent antipyretic and analgesic actions but with very weak anti-inflammatory 
activity. When administered to humans, it reduces levels of prostaglandin 
metabolites in urine but does not reduce synthesis of prostaglandins by blood 
platelets or by the stomach mucosa. Paracetamol is also a weak inhibitor in vitro of 
both cyclooxygenase (COX)–1 and COX-2 (Botting, 2000).   
 
1.5.2 Pharmacokinetics 
Paracetamol is rapidly absorbed from the gastrointestinal tract and distributed 
throughout most body tissues. The plasma half-life is 1 to 4 hours (Qing et al., 2005), 
but may be increased by liver damage and following overdosage. Paracetamol is 
eliminated principally by liver metabolism (conjugation) and subsequent renal 
excretion of metabolites. Approximately 85% of an oral dose appears in the urine 
within 24 hours of administration, mostly as the glucuronide conjugate, with small 
amounts of other conjugates and unchanged drug. 
 
1.6 Verapamil hydrochloride 
Chemical name of verapamil HCl is [DL-2-(3, 4-dimethoxyphenyl)-2-isopropyl-5-
(N-methyl-N-ß (3, 4- dimethoxyphenyl) ethylamino) valeronitrile] (Cole et al., 
1981). The empirical formula is C27H38N2O4 and chemical structure of verapamil 
HCl is shown in Fig.1.5.  
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Fig.1.5: Structural formula of verapamil HCl 
 
 
Molecular weight of verapamil HCl is 491.07 and melting point is in the range of 
1400C and 1440C (USP 21). Verapamil HCl is a white crystalline powder with no 
described odor and has a bitter taste. Verapamil HCl is weakly basic drug with pKa 
9.04 and log P value 4.6 (Christel et al., 2004). According to BCS, it is a class I drug 
(high soluble and high permeable drug) (Chi-Yuan and Leslie, 2005). Verapamil is 
soluble in water, methanol and chloroform. But the solubility is pH dependent and 
80-90 mg/ml soluble at pH 2.3 to 6.4 where the ionize species predominates.  
However, the solubility decreases rapidly at high pH. The solubility of verapamil 
HCl at pH 6.76 is 11 mg/ml (chang, 1988). 
 
1.6.1 Clinical pharmacology 
Verapamil is a synthetic paraverin derivate, belongs to phenylalkylamine class. 
Verapamil is a calcium channel blocker and important therapeutic agent for treatment 
of angina pectoris, essential hypertension and arrhythmia (Singh et al., 1978; 
Hamann et al., 1983; Garcia et al., 1997). 
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1.6.1 (a) Angina  
The two mechanisms of verapamil HCl as an antianginal activity are: 
 
Relaxation and prevention of coronary artery spasm  
Verapamil dilates the main coronary arteries and coronary arterioles, both in normal 
and ischemic regions. It is a potent inhibitor of coronary artery spasm, whether 
spontaneous or ergonovine-induced. This increases myocardial oxygen delivery in 
patients with coronary artery spasm which responsible for the effectiveness of 
verapamil in vasospastic (Prinzmetal’s or variant) as well as unstable angina at rest.  
 
Reduction of oxygen utilization 
Verapamil regularly reduces the total peripheral resistance (after load) against the 
heart works both at rest and at a given level of exercise by dilating peripheral 
arterioles. This unloading of the heart reduces myocardial energy consumption and 
oxygen requirements and probably accounts for the effectiveness of verapamil in 
chronic stable effort angina. 
 
The mechanism of the antianginal effect of verapamil HCl is believed to be related to 
its specific cellular action of selectively inhibiting trans-membrane influx of calcium 
in cardiac muscle, coronary and systemic arteries and in cells of the intracardiac 
conduction system. Verapamil blocks the trans-membrane influx of calcium through 
the slow channel (calcium ion antagonism) without affecting to any significant 
degree the transmembrane influx of sodium through the fast channel. This results in a 
reduction of free calcium ions available within cells of the above tissues. 
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1.6.1 (b) Essential hypertension 
Verapamil exerts antihypertensive effects by inducing peripheral vasodilation and 
reducing peripheral vascular resistance usually without reflex tachycardia. These 
effects are mediated by inhibition of calcium ion influx into smooth muscle cells of 
the arteriolar wall.  
 
1.6.1 (c) Arrhythmia 
The antiarrhythmic effects of verapamil HCl are largely due to its action on the 
sinoatrial (SA) and atrioventricular (AV) nodes. Verapamil HCl depresses AV nodal 
conduction and prolongs functional refractory periods. Verapamil HCl does not alter 
the normal atrial action potential or intraventricular conduction time, but depresses 
amplitude, velocity of depolarization and conduction in depressed atrial fibers. 
Through this action, it interrupts re-entrant pathways and slows the ventricular rate.  
 
1.6.2 Pharmacokinetics 
More than 90% of the orally administered dose of verapamil HCl is absorbed (Jhee et 
al., 2005). Due to the rapid biotransformation of verapamil during its first pass 
through the portal circulation, bioavailability ranges from 20 to 35%. Verapamil HCl 
has non-linear pharmacokinetics because of its saturation kinetics (first pass 
metabolism) which leads to non-linear absorption (Eichelbaum et al., 1981; Hamann 
et al., 1984; Vogelgesang et al., 1984; Follath et al., 1986; Lunden, 1991). The 
plasma half life of verapamil ranges from 3 to 7 hours (Baselt, 1982; Barbieri et al., 
1985; Meredith et al., 1985; Piotrovskii et al., 1986). 
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Verapamil undergoes extensive metabolism in the liver. Twelve metabolites have 
been identified in plasma (Wieslaw et al., 2001), out of which only norverapamil was 
found in significant amount whereas other metabolites were in trace amounts. 
Norverapamil can reach steady-state plasma concentrations approximately equal to 
those of verapamil itself. The cardiovascular activity of norverapamil appears to be 
approximately 20% that of verapamil. Approximately 70% of an administered dose 
is excreted as metabolites in the urine and 16% or more in the feces within 5 days. 
About 3 to 4% is excreted in the urine as unchanged drug. 
 
1.7 Release retarding agents for controlled drug delivery 
Polymers have gained in importance in the pharmaceutical industry as both drug 
encapsulants and vehicles of drug carriage either protecting an active agent during its 
passage through the body or in storage by preventing moisture ingress (Udeala and 
Aly, 1989) until its release, or controlling its release. Oral controlled release systems 
utilize principles such as diffusion, dissolution and permeation for achieving a 
constant rate of drug delivery. Polymers are research materials for the preparation of 
oral delivery systems. They offer a wide range of properties such as diffusivity, 
permeability and solubility that are important for achieving controlled delivery. They 
can be processed relatively easy into tablets and membrane by a variety of methods. 
Drugs can be dissolved in a polymer to manufacture matrix type oral dosage forms. 
Some of the polymers that are commonly used to develop matrix tablets are 
hydroxypropylmethyl cellulose, sodium carboxymethylcellulose, polyacrylic acid 
and polyethylene oxide (hydrophilic polymers) which are water soluble and ethyl 
cellulose, carbomers and waxes (hydrophobic polymers) which are water insoluble. 
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The properties of few hydrophilic and hydrophobic polymers used to develop a 
matrix tablets are given below.  
 
1.7.1 Hydroxypropylmethyl cellulose 
Hydroxypropylmethyl cellulose (HPMC) is white amorphous powder, with no odor 
and taste. The hydration rate of HPMC increases with an increase in the 
hydroxypropyl content. HPMC dissolves in cold water to form a viscous solution, 
but is not very soluble in hot water. Additionally it is soluble in mixture of water and 
alcohol, mixture of ethanol and dichloromethane and mixture of methanol and 
dichloromethane (Archer et al., 1992; Kumar et al., 1993; Budavari et al., 1996). 
Chemical name of HPMC is propylene glycol ether of methylcellulose. Chemical 
structure of HPMC is shown in Fig.1.6. HPMC is a methylcellulose modified with a 
small amount of propylene glycol ether groups attached to the anhydroglucose of the 
cellulose. The dry product contains 19 to 30% of methoxyl (-OCH3) groups and 3 to 
12% of hydroxypropyl (-OCH2CHOHCH3) groups.  
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Fig.1.6: Structural formula of hydroxypropylmethyl cellulose 
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HPMC is an inert hydrophilic polymer with no ionic charge. HPMC is available in 
several grades that vary in viscosity and extent of substitution. The viscosity grade of 
the polymer depends on the number of substituents on the polymeric backbone and 
the length of the cellulose chain. The molecular weight is approximately 10,000-
1,500,000 (Harwood, 2005). 
 
HPMC is used as a rate-controlling polymer for sustained release, coating agent, film 
former, stabilizing agent, suspending agent, tablet binder and viscosity increasing 
agent. In oral products, HPMC is primarily used as a tablet binder (Chowhan, 1980), 
film coating agent (Okhamafe and York, 1982) and as a matrix material for extended 
release tablet formulation (Dahl et al., 1990).   
 
1.7.2 Polymethacrylates  
Polymethacrylates are synthetic cationic and anionic polymers of diethylamino 
ethylmethacrylates, methacrylic acid and methacrylic acid esters in varying ratios. 
Eudragit polymers are copolymers of acrylic and methacrylic acid or their esters. 
They all have the same basic structure as shown in Fig.1.7. Their specific properties 
are determined by different functional groups R1 to R3 and different ratios of acrylic 
to methacrylic acid on one hand, and free acids to esters on the other hand. Eudragit 
is insoluble in water but it swells, which enables the incorporated drugs to be 
released from the formulation by means of diffusion through the swollen matrix. 
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Fig.1.7: Structural formula of Eudragit 
 
 
Polymethacrylates are primarily used in oral capsule and tablet formulations as film-
coating agents (Lehmann and Dreher, 1973; Lehmann, 1973a; Lehmann, 1973b; 
Gurry et al., 1977; Dew et al., 1982; Lehmann, 1986; Caneron and McGinity, 1987; 
Okor and Obi, 1990; Beckert et al., 1996; Jovanovic et al., 1997). Depending on the 
type of polymer used, films of different solubility characteristics can be produced. 
Eudragit RL, RS and NE 30 D are used to form water insoluble film coats for 
sustained release products. Polymethacrylates are also used as binders in both 
aqueous and organic wet granulation process. Larger quantities (5-20%) of dry 
polymer are used to control the release of an active substance from a tablet matrix.  
 
1.7.3 Eudragit L 100-55 
Eudragit L 100-55 is an anionic copolymer of methacrylic acid and ethyl acrylate. 
The ratio of the free carboxyl groups to the ester groups is approximately 1:1.  
Eudragit L 100-55 structural formula is shown in Fig.1.8. 
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Fig.1.8: Structural formula of Eudragit L 100-55 
 
Eudragit L 100-55 is soluble in water at pH 5.5 and above (Zahirul et al., 1999). 
Eudragit L 100-55 can be used for enteric coatings and a targeted delivery in the 
duodenum or jejunum. It is also used as enteric polymer for pH independent release 
of weakly basic drugs, because incorporation of acidic polymer in matrices would 
lead to lowering of the microenvironmental pH of the matrices (Aditya et al., 2004).  
 
1.7.4 Eudragit S 100  
 
Eudragit S 100 is an anionic copolymer of methacrylic acid and methyl methacrylate 
with free carboxyl groups in powder form. Eudragit S 100 structural formula is 
shown in Fig.1.9. The ratio of the free carboxyl groups to the ester groups is 
approximately 1:2. The polymer is soluble in water above pH 6.0 (Zahirul et al., 
1999). But due to the lower content of free carboxyl groups, it dissolves less rapidly 
than Eudragit L 12.5 and Eudragit L 100-55. It can be used for a targeted delivery in 
the ileum or colon. The site of drug release and the release-rate of drug from the 
dosage form can be altered by a combination with different types of Eudragit L. 
These polymers provide pH independent drug release that can be used for 
formulating the sustained release oral dosage forms.  
